GRAIL Stock Falls 20% After NHS Cancer Detection Trial Misses Primary Endpoint
GRAIL's NHS-Galleri trial, released February 1, 2026, failed to show a statistically significant reduction in late-stage cancer detection, its primary endpoint. The miss throws FDA approval into uncertainty and has driven shares down more than 20% in 2026. GRAIL is pivoting toward out-of-pocket direct-to-consumer sales while awaiting a critical data presentation at ASCO 2026.
Salvado•